"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
| Descriptor ID |
D018719
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
|
| Concept/Terms |
Receptor, ErbB-2- Receptor, ErbB-2
- ErbB-2 Receptor
- Antigens, CD340
- CD340 Antigens
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- p185(c-neu)
- c-erbB-2 Protein
- c erbB 2 Protein
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Receptors, erbB-2
- erbB-2 Receptors
- Neu Receptor
- Receptor, Neu
- Metastatic Lymph Node Gene 19 Protein
- Proto-oncogene Protein Neu
- Neu, Proto-oncogene Protein
- Proto-oncogene c-ErbB-2
- c-ErbB-2, Proto-oncogene
- Tyrosine Kinase-type Cell Surface Receptor HER2
- Tyrosine Kinase type Cell Surface Receptor HER2
- p185erbB2 Protein
- CD340 Antigen
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-2 [D12.776.543.750.630.009.400]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Receptor, ErbB-2 [D23.050.301.500.600.700]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Receptor, ErbB-2 [D23.050.705.552.600.550]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-2 [D23.101.140.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".
This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 4 | 2 | 6 |
| 2005 | 5 | 4 | 9 |
| 2006 | 2 | 6 | 8 |
| 2007 | 4 | 5 | 9 |
| 2008 | 6 | 7 | 13 |
| 2009 | 3 | 2 | 5 |
| 2010 | 7 | 8 | 15 |
| 2011 | 8 | 6 | 14 |
| 2012 | 5 | 5 | 10 |
| 2013 | 5 | 6 | 11 |
| 2014 | 4 | 5 | 9 |
| 2015 | 7 | 7 | 14 |
| 2016 | 4 | 6 | 10 |
| 2017 | 2 | 6 | 8 |
| 2018 | 6 | 8 | 14 |
| 2019 | 10 | 4 | 14 |
| 2020 | 7 | 2 | 9 |
| 2021 | 4 | 11 | 15 |
| 2022 | 2 | 6 | 8 |
| 2023 | 0 | 9 | 9 |
| 2024 | 6 | 2 | 8 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.
-
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies. Clin Cancer Res. 2025 Jan 17; 31(2):288-298.
-
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov. 2025 Jan 13; 15(1):119-138.
-
A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors. J Transl Med. 2025 Jan 09; 23(1):37.
-
ASO Visual Abstract: Real-World Implications of the SOUND Trial. Ann Surg Oncol. 2025 Jan; 32(1):121-122.
-
HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.
-
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb; 21(3):303-311.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2025 Feb; 23(1):102284.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.